Life Sciences

What life sciences businesses need to know about data commercialisation

A strategy for protecting and exploiting data is now a must for entities involved in healthcare research

What life sciences businesses need to know about data commercialisation
IV taps local partners to roll out licensing programme aimed at Chinese SMEs
25 Feb 2021

IV taps local partners to roll out licensing programme aimed at Chinese SMEs

Intellectual Ventures is just the latest big IP market player to set its sights on China, with a new programme COO Arvin Patel says is the first of its kind

How hub-and-spoke businesses are creating new pharma IP monetisation models
23 Feb 2021

How hub-and-spoke businesses are creating new pharma IP monetisation models

The launch of Centessa is the latest development in a trend that has big implications for the monetisation of unpartnered or deprioritised IP-backed pharma assets

Latest

View all
18 Feb 2021

Seven top IP tips for biotech SMEs

How smaller biotechs can best overcome pitfalls and maximise the value of their inventions Read more

16 Feb 2021

The CAFC’s Amgen v Sanofi decision spells trouble for broad functional patent claims

The CAFC’s much-anticipated ruling has major implications for antibody patents and continues the court’s trend of imposing a tough enablement standard for genus claims Read more

15 Feb 2021

Uptrend in oppositions could spell costly delays for Indian patent applicants

Practitioners say greater attention to detail during the prosecution process can head off frivolous challenges Read more

11 Feb 2021

How the rise of PTAB discretionary denials impacts Hatch-Waxman strategies

The recent rejection of a Mylan IPR petition – currently being challenged at the Federal Circuit – is good news for pharma patentees and bad news for generics Read more

News

View all
18 Dec 2020

Japan’s leading corporate IP departments revealed

The country's Asia IP Elite made some big strategic shifts in 2020 as they weathered an unprecedented year Read more

17 Dec 2020

China’s top in-house IP teams revealed

In a year marked by resilience, Chinese IP giants are pushing to close the gap with overseas competitors Read more

14 Dec 2020

The Asia IP Elite – a shared commitment to excellence across very different markets

IAM reveals the top in-house IP teams from India, Southeast Asia and Australasia Read more

19 Nov 2020

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations Read more

Analysis

View all
9 Feb 2021

Five IP takeaways from Jazz Pharmaceuticals’ $7 billion medical cannabis buyout

A major milestone in the medical cannabinoid patent market has been passed Read more

8 Feb 2021

Record French damages award is a good sign for pharma patentees

Recent decision to award Eli Lilly a preliminary injunction and damages in case against a generic company demonstrates an increasingly pro-rights holder approach on the part of a key French court Read more

6 Feb 2021

No, IP rights are not the barrier to covid-19 vaccine supplies

Continued criticism of biopharma patent owners fails to acknowledge that manufacturing and supply complexities are the real obstacles to mass inoculation around the world Read more

4 Feb 2021

SCOTUS’ denial of certiorari in Idenix v Gilead poses especially difficult IP questions for universities and small biotechs

Recent caselaw has raised serious doubts over the enforceability of US genus claims, leaving life sciences innovators in a quandary Read more

Insights

View all
12 Aug 2020

IP market news highlights

A rundown of some of the top news stories on the IAM platform in May, June and July Read more

12 Aug 2020

As the fallout from covid continues, the two IP superpowers offer different messages

While China cheers an uptick in applications, the USPTO warns of a prolonged downturn Read more

8 Jun 2020

IP Market news highlights

IAM’s biggest spring reads Read more

8 Jun 2020

From French fancy to global community – celebrating 100 issues of IAM 

Founder and editor in chief Joff Wild looks back on 17 years of IAM Read more